Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography

被引:8
作者
Bardelmeijer, HA
Ouwehand, M
Beijnen, JH
Schellens, JHM
van Tellingen, O
机构
[1] Netherlands Canc Inst, Dept Clin Chem, Antoni Van Leeuwenhoek Hosp, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Pharm & Pharmacol, Slotervaart Hosp, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Med Oncol, Antoni Van Leeuwenhoek Hosp, NL-1066 CX Amsterdam, Netherlands
[4] Univ Utrecht, Fac Pharm, Div Drug Toxicol, NL-3584 CA Utrecht, Netherlands
来源
JOURNAL OF CHROMATOGRAPHY B | 2001年 / 763卷 / 1-2期
关键词
cyclosporin A;
D O I
10.1016/S0378-4347(01)00389-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An isocratic reversed-phase high-performance liquid chromatographic method with ultraviolet detection at 227 run has been validated for the determination of cyclosporin A in human and mouse plasma. The cyclosporin D analog PSC 833 was used as internal standard. Plasma samples were pretreated by Equid-liquid extraction with diethyl ether. A good chromatographic separation between cyclosporin A, the internal standard and two potentially interfering endogenous peaks was achieved using a stainless steel column packed with 5 mum Nova-Pak phenyl material operated at 72 degreesC, and a mobile phase consisting of acetonitrile-methanol-water (20:52:28, v/v/v). The calibration curve for cyclosporin A in human plasma was linear over the tested concentration range of 0.11 to 5.34 muM. Murine plasma samples (200 mul) were diluted up to a total volume of 500 mul with blank human plasma and the concentrations were read from the calibration curve prepared in human plasma. The lower limit of quantitation was 0.11 muM using 500 mul of human plasma and 0.28 muM using 200 mul of mouse plasma. The validation data showed that the assay is sensitive, selective and reproducible for determination of cyclosporin A. The applicability was demonstrated in a pharmacokinetic experiment where mice received oral cyclosporin A. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 14 条
[1]  
ANTELLINGEN O, 2001, TOXICOL LETT, V120, P31
[2]   INVESTIGATION OF THE MECHANISM OF PEAK BROADENING OBSERVED IN THE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF CYCLOSPORINE [J].
BOWERS, LD ;
MATHEWS, SE .
JOURNAL OF CHROMATOGRAPHY, 1985, 333 (01) :231-238
[3]   MULTIDRUG-RESISTANCE GENE (P-GLYCOPROTEIN) IS EXPRESSED BY ENDOTHELIAL-CELLS AT BLOOD-BRAIN BARRIER SITES [J].
CORDONCARDO, C ;
OBRIEN, JP ;
CASALS, D ;
RITTMANGRAUER, L ;
BIEDLER, JL ;
MELAMED, MR ;
BERTINO, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (02) :695-698
[4]   THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE [J].
ENDICOTT, JA ;
LING, V .
ANNUAL REVIEW OF BIOCHEMISTRY, 1989, 58 :137-171
[5]   SURFACE GLYCOPROTEIN MODULATING DRUG PERMEABILITY IN CHINESE-HAMSTER OVARY CELL MUTANTS [J].
JULIANO, RL ;
LING, V .
BIOCHIMICA ET BIOPHYSICA ACTA, 1976, 455 (01) :152-162
[6]  
MCCOY HG, 1991, PHARMACOTHERAPY, V11, pS165
[7]  
Scott MG, 1997, CLIN CHEM, V43, P505
[8]   Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine [J].
Sparreboom, A ;
vanAsperen, J ;
Mayer, U ;
Schinkel, AH ;
Smit, JW ;
Meijer, DKF ;
Borst, P ;
Nooijen, WJ ;
Beijnen, JH ;
vanTellingen, O .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) :2031-2035
[9]  
Terwogt JMM, 1999, CLIN CANCER RES, V5, P3379
[10]   Co-administration of cyclosporin enables oral therapy with paclitaxel [J].
Terwogt, JMM ;
Beijnen, JH ;
Huinink, WWT ;
Rosing, H ;
Schellens, JHM .
LANCET, 1998, 352 (9124) :285-285